Saqib Islam was appointed Chief Executive Officer of SpringWorks Therapeutics in 2018. He was a founding member of the company’s executive team since its launch in 2017 and previously served as Chief Financial Officer and Chief Business Officer of the company. Prior to joining SpringWorks, Saqib was Chief Business Officer at Moderna Therapeutics, where he oversaw critical aspects of the company’s growth, including global strategic planning, corporate development and business development. Prior to Moderna, Saqib served as Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Saqib has over 25 years of international business management experience and an extensive background in the healthcare banking sector, having held managing director positions in the investment banking divisions of Morgan Stanley and Credit Suisse Securities. He currently serves on the Board of Directors of ARYA Sciences Acquisition Corp III, Passage Bio (where he also serves as a member of its Audit Committee), and Silverback Therapeutics (where he also serves as a member of its Compensation Committee).

Saqib received his bachelor’s degree from McGill University, graduating as a Faculty and University Scholar, and a J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar.

Dr. Badreddin Edris is responsible for corporate strategy, business development and capital formation. His professional experience spans private and public equity investing, company formation and operations, corporate and business development, and strategic and product planning in the biotechnology industry. Prior to joining SpringWorks Therapeutics, Badreddin was an investment and operating professional on the private equity team at OrbiMed, where he was involved in deal sourcing, evaluation and execution, as well as post-investment strategic and operational support for biotechnology companies across a range of therapeutic areas and stages of development. Badreddin also co-founded and held operating roles at two OrbiMed portfolio companies, Silverback Therapeutics (where he was Chief Business Officer) and Edgewise Therapeutics (where he was Chief Operating Officer). Before OrbiMed, Badreddin was a management consultant at Bain & Company, where he collaborated with global pharmaceutical and biotechnology companies on a range of strategic and operational projects.

Badreddin received his Ph.D. in genetics from Stanford University, where he was an NSF research fellow.

Bhavesh Ashar is Chief Commercial Officer of SpringWorks Therapeutics and brings more than 20 years of global pharmaceutical and biotechnology experience to the role. Prior to joining SpringWorks, Bhavesh was Senior Vice President, General Manager of U.S. Oncology at Bayer Healthcare, where he served as Business Unit head for the U.S. Oncology franchise and was responsible for a broad portfolio in prostate, liver, colorectal, GIST, hematologic and tumor-agnostic biomarker driven cancers. Prior to joining Bayer in 2017, Bhavesh held roles of increasing responsibility at Sanofi Genzyme over a 15-year tenure, including Vice President, General Manager of U.S. Oncology and Vice President, Global Head of Transplant. Prior to Sanofi Genzyme, Bhavesh was a consultant with McKinsey & Company where he served clients in the biopharmaceutical space.

Bhavesh received an MBA from the University of Chicago and a B.S. in mathematics from the Imperial College in London.

Dr. Mike Burgess is Head of Research and Development (R&D) at SpringWorks Therapeutics. He brings over 20 years of experience building and leading R&D teams in oncology. Prior to joining SpringWorks, Mike was President of R&D at Turnstone Biologics where he led the buildout of a leading cancer immunotherapy R&D organization. Before Turnstone, Mike led the strategy and execution of translational medicine, early-stage clinical trials and clinical pharmacology across all therapeutic areas, including oncology, at Bristol-Myers Squibb. Before that, he held several different senior leadership positions at Hoffmann La-Roche, including Acting Global Head of Roche Pharma Research and Early Development (pRED) and Senior Vice President and Global Head of Oncology Research and Early Development. Prior to Roche, Mike was with Eli Lilly and Company, where he worked on early-stage oncology trials.

Mike received his medical degree (M.B.Ch.B.) and Ph.D. in molecular biology from the University of Bristol, UK and spent 10 years as a practicing physician in pediatrics and pediatric oncology.

Frank Perier is Chief Financial Officer of SpringWorks. He was previously Chief Financial Officer at Forest Laboratories, Inc. for ten years prior to the company’s acquisition by Actavis. Prior to joining Forest, Frank was with Bristol-Myers Squibb Company for approximately nine years, where he worked in corporate and operations finance capacities of increasing responsibilities, including Vice President of Finance and Operations Planning – Americas Medicines Group, the company’s largest business unit at that time. Before joining Bristol-Myers Squibb, he was an accounting and auditing partner at Deloitte, where he worked for about 15 years. Frank was a member of the Board of Directors of Concordia International, Inc., a specialty pharmaceutical company, until September 2018 where he served on the Audit and the Human Resources and Compensation Committees of the Company.

Frank received an MBA from the Stern School of Business, New York University and a B.S. in accountancy from Villanova University. He is a Certified Public Accountant (inactive) and a member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.

Daniel Pichl is an accomplished human resources executive who joined SpringWorks Therapeutics from Siemens Healthineers, USA where he was Senior Vice President, Head of Human Resources and Global HR Business Partner for the Ultrasound division. At Siemens, he had global responsibility for People Strategy, Employee Relations, Compensation & Benefits, Talent Acquisition, Talent & Performance Management, Leadership Development, and Learning. Prior to this role, he served as Vice President, Head of People & Leadership for the Americas region, and before that, he held positions of increasing responsibility at Siemens AG, Germany.

Daniel earned a Master of International Business degree from Macquarie University in Sydney, Australia, and a Master of Psychology degree from Ludwig-Maximilians-University in Munich, Germany.

Dr. James (Jim) Cassidy is Chief Medical Officer of SpringWorks. He has over 30 years of experience in oncology as an academic physician-scientist and a drug development leader in both biotechnology and pharmaceutical companies, with experience spanning from early-stage research to translational and clinical development to post-marketing medical affairs strategy and lifecycle management. Prior to joining SpringWorks, he was Vice President of Oncology Strategic Program Direction at Regeneron Pharmaceuticals. Prior to this role, Jim was Corporate Vice President of Translational Development at Celgene, where he oversaw translational science efforts for the company’s entire portfolio of programs addressing both hematological malignancies and solid tumors. Before that, he was Vice President of Oncology at Bristol-Myers Squibb, where he was responsible for all oncology assets from development candidate nomination through clinical proof-of-concept studies, including biomarkers and translational research, and was closely involved with late-stage development, commercial, and business development efforts as well. Prior to Bristol-Myers Squibb, Jim held several roles of increasing responsibility at Hoffmann La-Roche, including Global Head of Translational Research for Oncology and Acting Head of the Oncology Therapy Area. Before joining Roche, Jim had been a leading academic physician-scientist, most recently having served as Professor of Oncology, Head of the Department of Cancer Research and Head of the Division of Cancer Sciences and Molecular Pathology at the University of Glasgow in Scotland.

Jim received his medical degree and doctorate from the University of Glasgow.

Dr. Mary Smith is responsible for designing and running the clinical development programs. Prior to joining SpringWorks Therapeutics, Mary was the Executive Vice President of Gene Therapy at Bamboo Therapeutics, a wholly owned subsidiary of Pfizer where she led several key gene transfer programs for rare genetic diseases. Prior to joining Bamboo, Mary was Vice President of product development at United Therapeutics, with responsibility for biological development in oncology, as well as regenerative medicine and virology.

Mary earned a Ph.D. in microbiology/immunology from the University of New Hampshire and received her post-doctoral training at Emory University.

Herschel Weinstein is General Counsel of SpringWorks Therapeutics. He was previously Vice Chair of the Life Sciences Group at Lowenstein Sandler LLP where he represented life sciences companies in licensing, acquisitions, collaborations and joint venture transactions. Prior to his role at Lowenstein, Herschel was General Counsel of Forest Laboratories, Inc. for approximately eight years prior to the company’s acquisition by Actavis. While at Forest, Herschel established the in-house legal function, was responsible for the significant licensing, collaboration and acquisition transactions that the company executed, served as Corporate Secretary for all Corporate Governance and Board matters, and provided legal support to all functions of the organization. Before joining Forest, Herschel served as outside counsel for the company over many years as a partner at the law firm Dornbush Schaeffer Strongin & Venaglia, LLP.

Herschel received a J.D. from Harvard Law School and a B.A. from Brandeis University.